Kornimate/medical-research-clean huggingface dataset:
use of n-acetylcysteine during liver procurement

Conditions: Liver Failure; Liver Failure, Acute; Liver Diseases; Carcinoma, Hepatocellular; Liver Neoplasms

Summary: randomized prospective study on the impact on the post-lt outcome by the infusion of n-acetylcysteine (nac) during the liver procurement procedure, as an anti-oxidant agent to reduce the ischemia-reperfusion damage of organs for liver transplantation (lt).

anti-oxidant agents have the potential to reduce the ischemia-reperfusion damage of organs for liver transplantation (lt). in this randomized prospective study, we seek to study the impact on the post-lt outcome of the infusion of n-acetylcysteine (nac) during the liver procurement procedure. potential grafts, assigned to adult candidates with chronic liver disease enlisted for first lt, will randomly be included in a one-to-one ratio with a sequential closed envelope single-blinded assignation procedure to either the nac protocol or in the standard procedure (without nac). the nac protocol comprises: a systemic nac infusion (30 mg/kg) one hour before the beginning of liver procurement; a loco-regional nac infusion (300 mg through the portal vein) just before cross-clamping.

Eligibility criteria:
inclusion criteria: * all consecutive subjects with chronic liver disease undergoing first liver transplantation receiving deceased donor livers exclusion criteria: * recipients with acute liver disease; * paediatric patients or adult patients receiving a liver from a paediatric donor; * patients undergoing multiple-organ transplantation; * patients undergoing re-transplantation of the liver; * patients undergoing living donor liver transplantation

Keywords: liver transplantation graft survival graft rejection primary graft dysfunction tissue and organ harvesting tissue and organ procurement tissue donors cold ischemia
china stroke registry for patients with traditional chinese medicine

Conditions: Ischemic Stroke; Intracerebral Hemorrhage

Summary: the cases-tcm study is a prospective, multicenter, observational study, which will enroll 20,000 patients with acute stroke (ischemic stroke or intracerebral hemorrhage) within 7 days of symptom onset. this study attempts to depict major clinical characteristics of acute stroke in patients with chinese medicine treatment and to explore any difference compared with other non-chinese medicine use cohorts and the effectiveness and safety of chinese medicine.


Eligibility criteria:
inclusion criteria: * ≥18 years of age * diagnosed as acute ischemic stroke or intracerebral hemorrhage * within 7 days of symptom onset exclusion criteria: * refusal to give informed consent * have difficulties completing follow-up
a study of icp-022 in patients with systemic lupus erythematosus (sle)

Conditions: Systemic Lupus Erythematosus

Summary: the purpose of the study is to assess the safety, tolerability, pk/pd and preliminary efficacy of icp-022 in subjects with systemic lupus erythematosus (sle)


Eligibility criteria:
inclusion criteria: 1. male or female subjects aged 18 to 75 2. diagnosis of with sle at least 6 months at screening visit 3. sledae-2k≥5 4. is receiving standard treatment for sle and has been receiving treatment for at least 3 months. 5. at least one sle activity manifestation (as assessed by sledae-2k) exclusion criteria: 1. failure to comply with the requirements of the programme 2. a female or male partner who is pregnant or breastfeeding or who plans to become pregnant during the study period 3. previously treated with a btk inhibitor 4. neuropsychiatric lupus (npsle) 5. has other autoimmune diseases other than sle note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: mild to moderate
preventive effects of cetylpyridinium chloride on sarcopeniastudy

Conditions: Sarcopenia

Summary: this study is to assess the impact on the prevention of sarcopenia after taking cetylpyridinium chloride targeting the patients of presarcopenia over the age of 60.

65 people that meet the inclusion criteria on screening test are assigned to one of five groups by randomization. they take the medication for two weeks under double-blind. four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks. control group takes the placebo for the same period. the main outcome variables are measured and compared respectively in baseline, immediately after dosing end and two weeks after the end of administration. finally cetylpyridinium chloride is verified whether it has a preventive effect on sarcopenia and set an appropriate dose.

Eligibility criteria:
inclusion criteria: * presarcopenia a. reduced skeletal muscle mass (asm/height2) m \ 0.8m/s * community dwelling exclusion criteria: * history of stroke or spinal cord injury * artificial joint * acute disease or unstable chronic disease * phenylketonuria * history of myocardiac infarction * allergic contact dermatitis * history of drug/alcohol addiction, habitual smoker

Keywords: sarcopenia cetylpyridinium chloride
ultrasound evaluation of the pelvis in women with suspected endometriosis scheduled for laparoscopic surgery

Conditions: Gynecologic Disease; Endometriosis; Endometriosis, Rectum; Endometriosis of Colon; Endometriosis of Vagina; Endometriosis Rectovaginal Septum; Endometriosis of Bladder; Surgery

Summary: an international multicenter observation study to evaluate the diagnostic accuracy and predictive value of ultrasound using the idea terminology in the detection of deep endometriosis in women scheduled for surgery.


Eligibility criteria:
inclusion criteria: * patients scheduled for radical laparoscopic endometriosis surgery exclusion criteria: * \<18 years * \>45 years * (suspected) pelvic malignancy for example gynecological, intestinal or urological malignancy * premenarche * menopause * pregnancy * patients refusal for radical surgery (for example refusal for bowel resection/temporary stoma) * surgery performed more than 1 year after ultrasound scan * patients refusal to participate to the study
elderberries and obesity

Conditions: Fuel Management

Summary: previous studies in humans indicate that anthocyanin-rich berries can positively alter fat oxidation and insulin sensitivity. this study will determine if this is also true with elderberries, which are a more concentrated source of anthocyanins compared to other commonly consumed berries.


Eligibility criteria:
inclusion criteria: women and men between 22 and 75 years of age with a body mass index of 25 kg/m2 or above. exclusion criteria: * are not fully vaccinated against covid-19 (at least 2-weeks out from final dose at time of staff meeting) * have a body mass index less than 25 kg/m2 * are younger than 22 years of age, or older than 75 years of age * pregnant, lactating, or intending to become pregnant during the study period, or have given birth in the past year * known allergy or intolerance to elderberries * history of bariatric surgery or nutrient malabsorption disease (such as celiac disease) or other metabolic disorders requiring a special diet that is not in accord with the diet behavior requested for this study * adherence to restrictive (vegetarian or vegan) or extreme (fad \[ex. ketogenic or atkins\] or quick weight loss/gain) diet patterns and unwillingness to consume a conventional, omnivorous diet and maintain body weight * habitual use of tobacco or marijuana (including vaping) products in the last 6 months * diagnosis or treatment of cancer in the past 3 years * crohn's disease or diverticulitis * suspected or known strictures, fistulas or physiological/mechanical gi obstruction * use of certain medications (prescription or over-the-counter) that may interfere with the study objectives, including blood thinning medications * type 2 diabetes requiring the use of medication * fasting blood glucose \> 125 mg/dl * unable or unwilling to give informed consent or communicate with study staff * self-report of alcohol or substance abuse within the past 12 months and/or current treatment for these problems (long-term participation in alcoholics anonymous is not an exclusion) * other medical, psychiatric, or behavioral factors that in the judgment of the principal investigator may interfere with study participation or the ability to follow the intervention protocol
a collaborative trial of niraparib to evaluate patients with ovarian cancer in the expanded access program in latin america

Conditions: Ovarian Cancer

Summary: data from niraparib treatment is not available in real-world setting in latin america. the present study aims to collect data from patients treated with niraparib within the latin america expanded access program (eap) in clinical practice in brazil and argentina and who meet the eligibility criteria for this study, without additional intervention.

this is a multicenter, retrospective and prospective (bi-directional) patient chart review, observational (non-interventional) study, in the patients treated within the latin america eap. the study is planned to be conducted at oncology services distributed in argentina and brazil. its multicenter nature aims to improve the representativeness of the study population in the region. patient's medical records will be screened by local clinical staff to assess for eligibility according to selection criteria in the sites previously involved in the eap. the follow-up data collection will be performed using a combination of medical records and patients' interviews. for patients that had interrupted the treatment before study start, the study comprises a single study visit with retrospective data collection from medical charts, followed by follow-up overall survival status, progression-free survival and time to next treatment performed by medical chart review or by phone call at month 12, month 24 and month 36 from the first dose of niraparib. for those that were still in treatment, data collection will be performed during the regular visits to the services involved in the study, using a combination of medical records abstraction and patient's interviews.

Eligibility criteria:
inclusion criteria: * patients with advanced oc in response following first line platinum-based chemotherapy who were treated with niraparib within the eap in argentina and brazil; * patients who have received at least one dose of niraparib in the eap. exclusion criteria: * patients without medical record available (lost, empty or irretrievable clinical information).
glutathione metabolism in adolescents with type 1 diabetes - study a

Conditions: Diabetes Mellitus, Type 1

Summary: glutathione is normally present at high (millimolar) levels in blood and plays an important role in the body's defense against oxidative stress, that is, against the damage caused to the body by reactive oxygen species produced by the metabolism of most nutrients, including glucose. glutathione is a small peptide made from 3 amino acids, glutamate, cysteine, and glycine. this study is looking at how blood sugar levels may affect the way glutathione is made and used by the body. since glutathione is continuously synthesized and broken down, the amount of glutathione present in blood depends on the balance between its rate of synthesis and its rate of use. in earlier studies, the investigators found that in poorly controlled diabetic teenagers, glutathione was low, not because its production was decreased, but because it was used at an excessive rate. in this study, the investigators want to determine how short-term changes in blood sugar levels affect glutathione levels. this will help improve our understanding of how diabetes affects metabolism.

adolescents with uncomplicated t1d will receive two, 5-hour infusions of deuterium-labeled cysteine on 2 separate days, a few weeks apart, while blood glucose will be maintained, using intravenous insulin infusion: * in the hyper-glycemic range (200-250 mg/dl) on one study day, and * near normoglycemia (80-140 mg/dl) on the other study day. the order of the study days will be randomized. we will determine whether the level of blood glucose at the time of study affects blood glutathione concentration, and, if so, whether this is associated with changes in the fractional rate of glutathione synthesis, as determined from the incorporation of labeled cysteine into blood glutathione over the course of the 5-hr infusion of labeled cysteine.

Eligibility criteria:
inclusion criteria: * type 1 diabetes, using usual criteria such as: glycosuria, hyperglycemia prior to treatment * bmi \<25 kg/m2 * age 14-18 * hba1c\>7.5% * no evidence of diabetic complications * written informed consent from parents or legal guardian, and assent from patient exclusion criteria: * presence of significant anemia (hemoglobin \<11g/dl) * presence of intercurrent illness such as infection * presence of chronic disease such as other endocrine deficiency, chronic respiratory or cardiac disease * chronic use of medication other than insulin * use of vitamin or mineral supplements within 2 weeks of study

Keywords: glutathione
comparative treatment study in patients with lower ureteral stones

Conditions: Urinary Calculi

Summary: we wish to determine the best treatment for expulsion of lower ureteral stones. which of the three major treatment protocols is the best treatment of conservative management of ureteral stones?

the study will include 60 patients with lower ureteral stones. the patients will be divided into three groups. the first group will be administered alfuzosin (10 mg). the second group will be administered a combination of alfuzosin (10 mg)and rowatinex (pinene 31%, camphene 15%, anetol 4%, borneol 10%, cineol 3%, fenchenol 4%, olive oil 33%). the third group will be administered rowatinex.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of lower ureter (urinary calculi) up to 8mm * must be able to swallow tablets exclusion criteria: * sensitivity to alfuzosin and rowatinex * pregnant and breastfeeding women * single kidney * obstructing stone * renal failure creatinine up to 1.8 mg/dl * patients using various alpha blockers * liver failure * fever higher than 38 c * uti * syncope or hypotension * patients treated with pde5 * patients treated with inhibitor cyp3a4 * patients refusing participation

Keywords: urinary calculi rowatinex alfuzosin drug therapy
unintentional weight loss and cancer: a prospective trial of patient-centered weight tracking combin

Conditions: Unintended Weight Loss

Summary: unintentional weight loss (uwl) is commonly associated with a wide variety of diseases and there is still no valid diagnostic pathway for evaluating uwl. when detecting uwl coupled with grail galleri testing, (an investigational pan-cancer early detection test), it is thought that there is a greater positive predictive value in detecting malignancies. this study aims to test the potential synergistic effects of uwl detection and grail usage to detect malignancy at an even earlier rate. uwl will be measured using weekly weight tracking.

enrolled participants will be provided with a fitbit aria smart scale and will be asked to weigh themselves each week at a similar time of day wearing a similar amount of clothing for a total of three years. these weight data will be automatically pushed to the fitbit cell phone application and patients who lost ≥5% from their baseline will be identified, and the intentionality of this weight loss (intentional or unintentional) will be assessed. all patients with uwl will be asked to have a grail galleri test, a health history and physical examination, a blood draw, imaging, routine cancer screenings done if not already completed, and referral to a specialist if a new cancer is detected.

Eligibility criteria:
inclusion criteria: * age range: from 40 to 80 years * access to a device (cellphone, computer, tablet) that is compatible with the fitbit aria air smart scale utilized in this study * willing to comply with all study procedures and be available for the duration of the study * subjects must be mentally competent and must have the ability to understand and the willingness to sign a written informed consent document * subjects must speak english to maximize chance of understanding the trial rational and study procedures exclusion criteria: * active cancer diagnosis - current diagnosis, currently undergoing cancer treatment, or concluded cancer treatments within 3 years * actively trying to lose weight with medications or bariatric surgery * pregnant

Keywords: grail galleri unintended weight loss uwl
non-invasive cardiac output monitoring in obstetric patients

Conditions: Complications; Cesarean Section; Anesthesia; Adverse Effect, Spinal and Epidural

Summary: the investigators hypothesize that continuously measuring stroke volume (sv) and cardiac output (co) will 1) reveal hemodynamic instability in a timely manner and alert the physician promptly, 2) provide information for the physician to make the differential diagnosis as to whether the hemodynamic instability was due to vasodilatation or reduction of venous blood return, and 3) lead to appropriate and prompt treatment to improve patient outcome. -determine the sv and co and their kinetic change using icon® to establish a hemodynamic profile of the patient under spinal anesthesia for cesarean section. to determine if using instantaneous measurements of sv and co to guide patient management improves hemodynamic stability.


Eligibility criteria:
inclusion criteria: * age 18-45; * receiving spinal anesthesia or combined spinal and epidural anesthesia to undergo cesarean section exclusion criteria: * patients who have major cardiovascular disease,preexisting of hypertension or gestational hypertension, preeclampsia and body mass index greater than 35kg/m2; * patients who have skin lesion at the place where the electrode is supposed to be applied; * emergency cesarean section patients.

Keywords: thoracic electric bioimpedance cardiac output monitoring cesarean section spinal anesthesia
the placental thickness and pregnancy outcomes in placenta previa women

Conditions: Placenta Accreta

Summary: placenta previa is the placenta overlying the cervical os. placenta previa is about 1 in 200 pregnancies. the risk factors are the increasing rate of cesarean section and previous uterine surgery. placenta previa is associated with many adverse complications; the most serious one is related to maternal hemorrhage. the diagnosis of placenta previa is done by trans-abdominal and trans-vaginal ultrasonography, which can document the placental edge's relationship to the internal os. placenta accreta spectrum disorder is defined when trophoblastic invades the myometrium. the placenta accreta spectrum can be categorized as: placenta accreta, placenta increta, and placenta percreta. the clinical utility of placental thickness is an area of ongoing research in placenta previa. prior studies have demonstrated an association between mid-trimester placental thickness and placenta accreta spectrum. despite the presence of many studies in characterizing placental thickness, most studies have focused primarily on the placental accreta spectrum lacking information about other fetal and maternal complications. symptomatic (bleeding) placenta previa is associated with increased maternal and neonatal morbidity and mortality. in addition; the mechanism that involves bleeding is unclear. it is usually related to uterine contractions, cervical effacement, and dilation leading to separation of the placenta from the underlying decidua.


Eligibility criteria:
inclusion criteria: 1. pregnant women from 32-34 weeks. 2. pregnant women with singleton pregnancy. 3. women with placenta previa. 4. placenta previa with minimal vaginal bleeding or haven't any vaginal bleeding. 5. women without any medical disorders. 6. women should be living in a nearby area to make follow-up and early transportation is reasonably possible. exclusion criteria: 1. women with severe bleeding necessitate immediate delivery. 2. women with confirmed fetal malformation. 3. if associated with abruptio placentae. 4. women who will refuse to participate.
fractional carbon dioxide laser versus uva 1 in treatment of localized scleroderma

Conditions: Localized Scleroderma

Summary: the study aims at evaluating the efficacy of the fractional carbon dioxide laser as a new modality for treatment of localized scleroderma and to compare its results with the well established method of uva 1 phototherapy.

the study includes 20 cases presenting with one or more lesions of morphea (plaque, linear and atrophic). each case will be subjected to: 1. -informed consent. 2-detailed history 3- clinical examination to assess type, site, extent. 4-clinical evaluation before treatment, in the follow up period and after treatment ( 24 sessions of uva1) (one month after last co2 laser session) using a scoring system: * skin thickness: 0-3, 0: normal; 1: thickened skin; 2: decreased ability to move the skin; 3: unable to pinch or move skin (according to the modified rodnan skin score) * dermal atrophy: 0-3, 0: none, 1: shiny, 2: visible vessels, 3: obvious atrophy * dyspigmentation (hypo or hyper pigmentation): 0-3, 0: none, 1: mild, 2: moderate ,3: marked c- digital photography before, follow up and after treatment using the same digital camera , at fixed distance and constant settings for standardization . 5-investigations: a- punch biopsy: a punch biopsy will be taken before and after treatment to be stained with haematoxylin and eosin. b-immunohistochemical assessment of * mmp1 (matrix metalloproteinase 1) in the pre and post treatment skin biopsies. * tgfß ( transforming growth factor beta)in the pre and post treatment skin biopsies. 6-treatment intervention: two lesions with identical scoring will be chosen for the treatment interventions. 1. lesion number (1) will be subjected to: localized uva1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment. 2. lesion number (2) will be subjected to: fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.

Eligibility criteria:
inclusion criteria: 1. types of morphea: plaque, linear and atrophic. 2. patients are either new or discontinued systemic treatment for at least two months exclusion criteria: 1. morphea profunda and systemic scleroderma (diagnosed by: rayaund's phenomenon and sclerodactyly +/- internal organ affection) 2. contraindications to phototherapy: eg: photosensitivity, systemic lupus, melanoma, skin cancer, or porphyria. 3. contraindications to laser: use of systemic retinoids in the last 6 months.

Keywords: localized scleroderma uva1 fractional carbon dioxide laser